Introduction
ovarian cancer, nausea and vomiting, High-grade serous ovarian carcinoma, Ovarian cancer, deaths, tumors
OVARIAN CANCER, RECURRENCE, RECURRENT OVARIAN CANCER, DISEASE, OVARIAN CANCER, EPITHELIAL OVARIAN CANCER, TUMORS
Ovarian cancer is diagnosed in an estimated 314,000 women worldwide annually accounting for approximately 207,000 deaths [High-grade serous ovarian carcinoma is the most common subtype of epithelial ovarian cancer. It is associated with a high frequency of inherited mutations; approximately 50% of tumors have genomic alterations causing deficiencies in homologous recombination repair [In the past two decades, the standard-of-care first-line treatment for patients with advanced ovarian cancer has been a platinum-based chemotherapy regimen consisting of carboplatin and paclitaxel. Despite initial positive clinical responses to this treatment, many patients develop resistance after the first or subsequent treatment cycles, with up to 70% reporting disease recurrence [PARP inhibitors, such as olaparib, rucaparib, and niraparib, have proven effective as single agents in treating patients with recurrent ovarian cancer and as maintenance therapy in patients who responded to platinum-based therapy [Veliparib (formerly ABT-888) is a potent, highly selective oral PARP-1 and -2 inhibitor shown to enhance the activity of DNA-damaging chemotherapy, including platinum agents [The phase 1 study confirming tolerability of veliparib monotherapy in Japanese patients reported nausea and vomiting in almost all patients (93.8% each), resulting in veliparib dose interruption, reduction, or discontinuation in most patients [